You are here

  • Home
  • Archive
  • Volume 11, Issue 10
  • Divergent tumor and immune cell reprogramming underlying immunotherapy response and immune-related adverse events in lung squamous cell carcinoma

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Divergent tumor and immune cell reprogramming underlying immunotherapy response and immune-related adverse events in lung squamous cell carcinoma

 

Online download statistics by month:

Online download statistics by month: October 2023 to March 2026

AbstractFullPdf
Oct 2023526527212
Nov 2023405411160
Dec 202317217393
Jan 2024208208144
Feb 202413313394
Mar 2024175175117
Apr 202414915187
May 2024180181104
Jun 2024153154124
Jul 2024218222128
Aug 2024139138134
Sep 202412512889
Oct 202414214585
Nov 202416817099
Dec 2024252259146
Jan 2025200200127
Feb 2025296296130
Mar 2025197198147
Apr 2025202205133
May 2025186188126
Jun 202513813881
Jul 2025110
Aug 2025110
Mar 2026110
Total436744032560